Cell and Gene Therapy Today—March 26, 2026

In Today’s Newsletter

Dive deeper

🧬 Belief BioMed wins Macao approval for BBM-H901 [1] [China • 19 Mar 2026]

https://www.prnewswire.com/news-releases/belief-biomed-announced-bbm-h901-dalnacogene-ponparvovec-injection-chinas-first-hemophilia-b-gene-therapy-was-officially-approved-in-macao-china-302718629.html
Context: BBM-H901 (Belief BioMed; AAV gene therapy for hemophilia B) previously approved in mainland China in 2025.
Key point: Macao regulator approved BBM-H901 for adults with moderate to severe hemophilia B.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Belief BioMed partners with Grand Life Sciences on BBM-H803 [2] [China • 23 Mar 2026]

https://www.prnewswire.com/news-releases/belief-biomed-and-grand-life-sciences-announced-exclusive-commercial-partnership-in-the-field-of-hemophilia-a-bringing-innovative-gene-therapy-to-chinese-patients-302721786.html
Context: BBM-H803 (Belief BioMed; investigational gene therapy for hemophilia A) is part of the company’s expanding pipeline.
Key point: Grand Life Sciences gained exclusive commercialization rights across Mainland China, Hong Kong, Macao, and Taiwan (terms not disclosed).
Implication: Signals pipeline investment and modality expansion.

🏥 Karmanos administers Hemgenix gene therapy [3] [US • 23 Mar 2026]

https://www.prnewswire.com/news-releases/karmanos-cancer-institute-becomes-first-and-only-free-standing-cancer-center-to-treat-hemophilia-b-with-new-gene-therapy-302720315.html
Context: Hemgenix (CSL Behring; AAV gene therapy for hemophilia B) is FDA approved as a one-time treatment.
Key point: Karmanos became the first independent US cancer center to deliver the therapy; long-term data cited show most patients stopped prophylaxis.
Implication: May expand screening, initiation, and follow-up at scale.

🧪 Cytiva and SR-TIGET launch genomic medicine collaboration [4] [23 Mar 2026]

https://www.fondazionetelethon.it/en/stories-and-news/news/from-telethon-foundation/cytiva-and-san-raffaele-telethon-institute-for-gene-therapy-sr-tiget-launch-collaboration-to-advance-next-generation-genomic-medicine-platforms/
Context: SR-TIGET (Italy) is a leading gene therapy institute; Cytiva is a Danaher company focused on bioprocessing.
Key point: Collaboration targets scalable lentiviral vector production and hematopoietic stem cell gene editing platforms.
Implication: Signals pipeline investment and modality expansion.

🏗️ SK pharmteco invests $100M in viral vector capacity [5] [23 Mar 2026]

https://www.biospectrumasia.com/news/51/27387/koreas-sk-pharmteco-to-invests-100m-to-bolster-global-gene-therapy-business.html
Context: SK pharmteco operates global CDMO sites in the US and Europe. Key point: Investment will expand viral vector manufacturing and operational infrastructure across key sites.
Implication: Signals pipeline investment and modality expansion.

👁️ Ocugen reports Phase 2 success for OCU410 [6] [US • 24 Mar 2026]

https://www.fiercebiotech.com/biotech/ocugen-eye-disease-gene-therapy-nabs-full-ph-2-win-underwhelms-investors
Context: OCU410 (Ocugen; AAV gene therapy for geographic atrophy) studied in a Phase 2 trial (n=51).
Key point: Trial met primary endpoint with lesion reduction and favorable safety; Phase 3 planned (investor reaction negative).
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Aspen reports 1-year data for sasineprocel [7] [US • 18 Mar 2026]

https://www.fiercebiotech.com/biotech/aspens-one-year-data-parkinsons-cell-therapy-plants-seeds-ph-3-trial
Context: Sasineprocel (Aspen Neuroscience; autologous neuron cell therapy) derived from patient skin cells.
Key point: Early-phase data (n=8) showed improvements in motor function and quality of life at 1 year.
Implication: May influence prescriber choice and payer reviews pending full data.

🚀 Oryon launches with neuron replacement therapy [8] [US • 23 Mar 2026]

https://www.businesswire.com/news/home/20260323924704/en/Oryon-Cell-Therapies-Emerges-From-Stealth-Focusing-on-Autologous-Neuron-Replacement-Therapies-for-Parkinsons-Disease-and-Other-Neurodegenerative-Disorders
Context: Oryon focuses on autologous neuron replacement for Parkinson’s and other neurodegenerative diseases.
Key point: Company raised $42M total and reported early clinical signals of motor improvement and dopaminergic activity.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

Gene therapy commercialization is accelerating in hemophilia, with approvals, partnerships, and real-world rollout all advancing in parallel [1][2][3].
Manufacturing scale and platform reliability remain central constraints, reflected in Cytiva and SK pharmteco investments [4][5].
Ophthalmology gene therapy continues to progress, though investor sensitivity to efficacy durability is واضح in Ocugen’s update [6].
Parkinson’s disease is emerging as a major frontier for cell therapy, with multiple autologous neuron approaches moving toward Phase 3 [7][8].
The field shows a balance between clinical validation, infrastructure build-out, and early commercialization pathways.

📚 See the full Cell and Gene Therapy archive on our research hub page.

🎬 Watch on YouTube. Subscribe and never miss a video.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What does BBM-H901 approval in Macao add beyond mainland China?

It extends access to another regulatory jurisdiction and may support broader international adoption strategies for Belief BioMed’s hemophilia B gene therapy [1].

What is the scope of the BBM-H803 partnership?

Grand Life Sciences will commercialize the hemophilia A gene therapy candidate across Greater China, aiming to accelerate patient access (terms not disclosed) [2].

How widely is Hemgenix being used in the US now?

Adoption is expanding center by center, with Karmanos marking a new type of site, an independent cancer center, entering the treatment network [3].

What problem does the Cytiva–SR-TIGET collaboration address?

It targets manufacturing and scalability bottlenecks, especially in lentiviral vectors and stem cell gene editing workflows [4].

Why did Ocugen’s positive data still disappoint investors?

Although OCU410 met its endpoint, the magnitude of effect was lower than earlier interim data, raising questions about consistency and expectations [6].

How do Aspen and Oryon approaches compare in Parkinson’s?

Both pursue autologous neuron replacement strategies; Aspen has reported small early clinical data, while Oryon is earlier-stage but backed by new funding and similar biology [7][8]

Entities / Keywords

Belief BioMed, BBM-H901, dalnacogene ponparvovec, BBM-H803, Grand Life Sciences, hemophilia A, hemophilia B
CSL Behring, Hemgenix, etranacogene dezaparvovec, Karmanos Cancer Institute
Cytiva, SR-TIGET, Danaher Beacon, lentiviral vectors, hematopoietic stem cells
SK pharmteco, viral vectors, CDMO, manufacturing
Ocugen, OCU410, geographic atrophy, AMD
Aspen Neuroscience, sasineprocel, Parkinson’s disease, autologous cell therapy
Oryon Cell Therapies, neuron replacement therapy, dopaminergic neurons